Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy

Circ Cardiovasc Imaging. 2013 Sep;6(5):627-36. doi: 10.1161/CIRCIMAGING.112.000367. Epub 2013 Jul 5.

Abstract

Background: Transthyretin familial amyloid polyneuropathy is a hereditary form of amyloidosis characterized by sensorimotor and autonomic neuropathy, cardiac conduction defects, and infiltrative cardiomyopathy. Previous studies have suggested that myocardial sympathetic denervation assessed by 123-iodine metaiodobenzylguanidine (MIBG) imaging occurs early in disease progression. However, its prognostic significance was never evaluated. We aimed to study the long-term prognostic value of myocardial sympathetic denervation detected by MIBG imaging in transthyretin familial amyloid polyneuropathy.

Methods and results: A total of 143 individuals with V30M transthyretin mutation underwent Holter, ambulatory blood pressure monitoring, echocardiography, and MIBG imaging. Time to all-cause death was compared with late heart-to-mediastinum MIBG uptake ratio (H/M; either in relation to the estimated lower limit of normal [1.60] or as a continuous variable) using Cox proportional hazards regression. Multivariable analyses were performed to test the prognostic accuracy of clinical, neurological, and cardiovascular parameters. During a median follow-up of 5.5 years, 32 (22%) patients died. Five-year mortality rate was 42% for late H/M <1.60 and 7% for late H/M ≥1.60 (hazard ratio, 7.19; P<0.001). Late H/M was identified as an independent prognostic predictor. Fifty-three patients were submitted to liver transplantation. In comparison with neurophysiological score-matched controls, transplanted patients had lower long-term mortality (hazard ratio, 0.32; P=0.012). Patients with late H/M<1.60 were at higher risk of unfavorable outcome but seemed to have benefited from liver transplantation.

Conclusions: Cardiac sympathetic denervation as assessed by MIBG imaging is a useful prognostic marker in transthyretin familial amyloid polyneuropathy.

Keywords: amyloid; prognosis; radionuclide imaging.

Publication types

  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • 3-Iodobenzylguanidine*
  • Adult
  • Aged
  • Aged, 80 and over
  • Amyloid Neuropathies, Familial / diagnostic imaging*
  • Amyloid Neuropathies, Familial / genetics
  • Amyloid Neuropathies, Familial / mortality
  • Amyloid Neuropathies, Familial / therapy
  • Cardiomyopathies / diagnostic imaging*
  • Cardiomyopathies / genetics
  • Cardiomyopathies / mortality
  • Cardiomyopathies / therapy
  • Echocardiography
  • Electrocardiography, Ambulatory
  • Female
  • Genetic Predisposition to Disease
  • Heart / innervation*
  • Humans
  • Kaplan-Meier Estimate
  • Liver Transplantation
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Mutation
  • Phenotype
  • Prealbumin / genetics
  • Predictive Value of Tests
  • Prognosis
  • Proportional Hazards Models
  • Prospective Studies
  • Radionuclide Imaging
  • Radiopharmaceuticals*
  • Reproducibility of Results
  • Risk Factors
  • Sympathetic Nervous System / diagnostic imaging*
  • Time Factors
  • Young Adult

Substances

  • Prealbumin
  • Radiopharmaceuticals
  • 3-Iodobenzylguanidine

Supplementary concepts

  • Amyloidosis, Hereditary, Transthyretin-Related